110 related articles for article (PubMed ID: 27590579)
1. Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.
Tipton AR; Nyabuto GO; Trendel JA; Mazur TM; Wilson JP; Wadi S; Justinger JS; Moore GL; Nguyen PT; Vestal DJ
Biochem Biophys Res Commun; 2016 Sep; 478(4):1617-23. PubMed ID: 27590579
[TBL] [Abstract][Full Text] [Related]
2. hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance.
Wadi S; Tipton AR; Trendel JA; Khuder SA; Vestal DJ
J Cancer Ther; 2016 Dec; 7(13):994-1007. PubMed ID: 28090373
[TBL] [Abstract][Full Text] [Related]
3. Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines.
Bernabeu E; Gonzalez L; Cagel M; Gergic EP; Moretton MA; Chiappetta DA
Colloids Surf B Biointerfaces; 2016 Apr; 140():403-411. PubMed ID: 26780253
[TBL] [Abstract][Full Text] [Related]
4. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
[TBL] [Abstract][Full Text] [Related]
5. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
6. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
Tommasi S; Mangia A; Lacalamita R; Bellizzi A; Fedele V; Chiriatti A; Thomssen C; Kendzierski N; Latorre A; Lorusso V; Schittulli F; Zito F; Kavallaris M; Paradiso A
Int J Cancer; 2007 May; 120(10):2078-85. PubMed ID: 17285590
[TBL] [Abstract][Full Text] [Related]
7. Coordinated regulation of β-tubulin isotypes and epithelial-to-mesenchymal transition protein ZEB1 in breast cancer cells.
Lobert S; Graichen ME; Morris K
Biochemistry; 2013 Aug; 52(32):5482-90. PubMed ID: 23869586
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity and apoptosis of ovarian and breast cancer cell lines induced by OVS1 monoclonal antibody and paclitaxel.
Moongkarndi P; Kaslungka S; Kosem N; Junnu S; Jongsomboonkusol S; Theptaranon Y; Neungton N
Asian Pac J Allergy Immunol; 2003 Mar; 21(1):31-41. PubMed ID: 12931749
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
10. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ; Lu P; Duan ZF; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
[TBL] [Abstract][Full Text] [Related]
11. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
12. [Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer].
Tang J; Cao L; Yi H; Tang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1221-7. PubMed ID: 23281375
[TBL] [Abstract][Full Text] [Related]
13. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
Duan Z; Lamendola DE; Duan Y; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
[TBL] [Abstract][Full Text] [Related]
14. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
15. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
16. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer.
Zhang SF; Wang XY; Fu ZQ; Peng QH; Zhang JY; Ye F; Fu YF; Zhou CY; Lu WG; Cheng XD; Xie X
Autophagy; 2015; 11(2):225-38. PubMed ID: 25607466
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
[TBL] [Abstract][Full Text] [Related]
18. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
20. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]